GlassScriptPhysician profile
Andrew J Stasevich
NPI 1043297955
$525.86
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.90 · 2023: $38.84 · 2024: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $449.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $77.07 | 2024 | |
| Exact Sciences Corporation | $75.97 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $55.42 | 2024 | |
| Novo Nordisk INC | $54.94 | 2019-2024 | Ozempic |
| Lilly USA, LLC | $51.82 | 2024 | Jardiance, Zepbound |
| Organon LLC | $36.99 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $29.13 | 2019 | |
| Tactile Systems Technology INC | $25.45 | 2024 | Entre Plus, Flexitouch Plus |
| Mylan Specialty L.P. | $22.04 | 2024 | Yupelri |
| Sumitomo Pharma America, INC. | $21.72 | 2023 | Myfembree |
| Phadia US INC. | $20.29 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.03 | 2024 | Zoryve |
| Antares Pharma, INC. | $14.02 | 2024 | Xyosted |
| Novartis Pharmaceuticals Corporation | $13.84 | 2019 | |
| Tolmar, INC. | $13.13 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Stasevich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.